Trial Profile

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amivantamab (Primary)
Indications Non-small cell lung cancer
Focus Pharmacodynamics
Acronyms RESAMEX

Most Recent Events

29 Apr 2026 Planned End Date changed from 30 Sep 2025 to 30 Jul 2026.
29 Apr 2026 Planned primary completion date changed from 30 Sep 2025 to 30 Jul 2026.
12 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com